Doctors Without Borders (MSF) has raised serious concerns over limited access to a groundbreaking HIV prevention drug, lenacapavir, after the pharmaceutical company Gilead Sciences declined to supply the medicine directly to the organization. The drug, an injectable form of pre-exposure prophylaxis (PrEP), represents a significant advancement in HIV prevention as it requires administration only twice a year, making it especially valuable for people in resource-limited and humanitarian settings where consistent access to daily medication can be challenging.
MSF has repeatedly requested access to lenacapavir for use in its global medical programs but has been directed instead to obtain the drug through the Global Fund to Fight AIDS, Tuberculosis and Malaria. However, the available supply through this mechanism is limited and insufficient to meet global demand, covering only a fraction of those who could benefit from the treatment. This has raised concerns about inequitable access, particularly for populations in low- and middle-income countries.
The situation highlights broader issues around the control of pharmaceutical production and distribution. Gilead currently holds authority over the manufacturing and allocation of lenacapavir, and access remains restricted in many of the countries where MSF operates. At the same time, the drug is available in wealthier markets, underscoring disparities in global health access and prompting comparisons to past challenges in the distribution of HIV treatments.
The stakes are particularly high given the continued global burden of HIV, with millions of new infections occurring each year. For vulnerable populations, including those in conflict zones and underserved regions, limited access to effective prevention tools can significantly increase the risk of infection and undermine efforts to control the epidemic.
MSF has called for urgent dialogue with Gilead to address the issue, including discussions on pricing, supply timelines, and direct access to the drug for humanitarian use. The organization argues that expanding access to lenacapavir is essential to ensuring equitable healthcare and preventing avoidable infections worldwide, especially among populations most at risk.
